DAVIS, Calif., Aug. 16, 2022 /PRNewswire/ -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today announced the closing of its previously announced registered direct offering of 4,722,506 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.05876 per share, priced at-the-market under Nasdaq rules. Additionally, in a concurrent private placement, Arcadia issued to the investors unregistered preferred investment options to purchase up to 4,722,506 shares of common stock. Each preferred investment option has an exercise price of $0.93376 per share, is exercisable immediately upon issuance and will expire five years from the issuance date.
Read more at prnewswire.com
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
